GlaxoSmithKline PLC will have a new opportunity to jumpstart sales of Breo Ellipta (fluticasone furoate/vilanterol) after FDA approved the drug as a once-daily treatment for asthma for patients 18 and older April 30.
The fixed-dose combination of the inhaled corticosteroid fluticasone and the long-acting beta2-agonist (LABA) vilanterol administered via the Ellipta dry powder inhaler has been on the market since October 2013 for...